BMS-986497

Near Add Your Location

Sorting 1 by

Accepting patients

BMS-986497 (ORM-6151)

Phase I Multicenter, Open-Label, First-in-Human Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double Combination With Azacitidine and in Triple Combination With Azacitidine and Venetoclax in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
  • GSPT1 Degrader
  • CD33
  • Phase 1